Supplementary Table S4. Activities and Metabolite Levels in Rats Treated with APAP

	Assay conditions	*Control* (n = 6)	*APAP* (n = 6)	p-*Value*
ALT (U/L)	Serum	28.33 ± 3.41	1324 ± 453[a]	< 0.0001
AST (U/L)	Serum	131.5 ± 22.32	2630 ± 1075.8[a]	< 0.0001
AdoMet (nmol/g)	Liver	77.43 ± 8.20	59.43 ± 5.05[a]	0.049
AdoHcy (nmol/g)	Liver	48.79 ± 5.33	30.82 ± 3.49[a]	0.045
AdoMet/AdoHcy	Liver	1.42 ± 0.08	2.33 ± 0.27[a]	0.001
Hcy (nmol/g)[b]	Liver	< 1.5	< 1.5	–
Methionine (nmol/g)	Liver	186.6 ± 38.90	94.88 ± 18.54[a]	0.012
GSH (nmol/mg protein)	Liver	77.31 ± 20.48	41.45 ± 10.37[a]	0.04
GSSG (nmol/mg protein)	Liver	1.58 ± 0.04	1.15 ± 0.05[a]	0.001
GSH/GSSG	Liver	47.87 ± 3.06	36.34 ± 6.28[a]	0.049
MAT [pmol/(min·mg^{-1})]	60 μM Met	161.5 ± 4.39	128.0 ± 4.91[a]	0.001
	60 μM Met + 10% DMSO	654.8 ± 25.21	611.4 ± 14.93	0.195
	5 mM Met	2389.0 ± 131.1	1957.0 ± 121.7[a]	0.027
MAT III/I activity ratio	5 mM Met	1.08 ± 0.11	2.35 ± 0.70[a]	0.016

ALT and aspartate aminotransferase activities were measured in serum samples of control and APAP-treated animals. On the other hand, metabolite levels and cytosolic MAT activity were determined in liver samples as described under the "Materials and Methods" section. The activity data shown are the mean ± SD of measurements made in triplicate for every individual in each group.

[a]Significant, $p \leq 0.05$.

[b]Below the quantification limit.

APAP, acetaminophen.